Future approaches to genetic toxicology risk assessment

Mutation Research - Reviews in Genetic Toxicology

Volumn 365, Issue 1-3, 1996, Pages 191-204

  Elespuru, Rosalie K ^a,b  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b Ctr for Devices and Radiological H   (United States)

Author keywords

DNA damage; genetic toxicology; risk assessment; short term test

Indexed keywords

CARCINOGEN; MUTAGENIC AGENT;

CARCINOGENESIS; DNA ADDUCT; DNA DAMAGE; FUTUROLOGY; GENOTOXICITY; HUMAN; MODEL; MUTAGEN TESTING; MUTAGENICITY; MUTATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT;

ANIMALIA;

EID: 0030250609     PISSN: 01651110     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-1110(96)90021-4     Document Type: Article

References (100)

1. Abe S., Sasaki M. Chromosome aberrations and sister chromatid exchanges in Chinese hamster ovary cells exposed to various chemicals. JNCI. 58:1977;1635-1641.
2. Aidoo A., Lyn-Cook L.E., Mittelstaedt R.A., Heflich R.H., Casciano D.A. Induction of 6-thioguanine-resistant lymphocytes in Fischer 344 rats following in vivo exposure to N-ethyl-N-nitrosourea and cyclophosphamide. Environ. Mol. Mutagen. 17:1991;141-151.
3. Albertini R.J. Why use somatic mutations for human biomonitoring? Environ. Mol. Mutagen. 23:(Suppl. 24):1993;18-22.
4. Albertini R.J., Nicklas J.A., O'Neill J.P., Robison S.H. In vivo somatic mutations in humans: measurement and analysis. Annu. Rev. Genet. 24:1990;305-326.
5. Ames B.N., Durston W., Yamasaki E., Lee F. Carcinogens are mutagens: a simple test system combining liver homogenates for activation and bacteria for detection. Proc. Natl. Acad. Sci. USA. 70:1973;2281-2285.
6. Applegate M.L., moore M.M., Broder C.B., Burrell A., Juhn G., Kasweck K.L., lin P.-F., Wadhams A., Hozier J.C. Molecular dissection of mutations at the heterozygous thymidine kinase locus in mouse lymphoma cells. Proc. Natl. Acad. Sci. USA. 87:1990;51-55.
7. Ashby J., Tennant R.W. Definitive relationships among chemical structure, carcinogenicity and mutagenicity for 301 chemicals tested by the US NTP. Mutation Res. 257:1991;229-306.
8. Ashby J.A., Waters M.D., Preston J., Adler I.-D., Douglas G.R., Fielder R., Shelby M.D., Anderson D., Sofuni T., Gopalan H.N.B., Sonich-Mullin C., Becking G. IPCS harmonization of methods for the prediction and quantification of human carcinogenic/mutagenic hazard, and for indicating the probable mode of action of known rodent carcinogens. Mutation Res. 352:1996;153-157.
9. Barrett J.C., T'so P.O.P. Evidence for the progressive nature of neoplastic transformation in vitro. Proc. Natl. Acad. Sci. USA. 75:1978;3761-3765.
10. Bartsch H., Malaveille C., Camus A.M., Martel-Planche G., Brun G., Hautefeuile A., Sabadie N., Barbin A., Kuroki T., Drevon C., Piccoli C., Montesano R. Validation and comparative studies on 180 chemicals with S. typhimurium strains and V79 Chinese hamster cells in the presence of various metabolizing systems. Mutation Res. 76:1980;1-50.
11. Berenblum I., Shubik P. A new quantitative approach to the study of the stages of chemical carcinogenesis in the mouse's skin. Br. J. Cancer. 1:1947;983-991.
12. Bos J.L. Ras oncogenes in human cancer: a review. Cancer Res. 49:1989;4682-4689.
13. Boutwell R.K. Some biological aspects of skin carcinogenesis. Prog. Exp. Tumor Res. 4:1964;207-250.
14. Brash D.E., Rudolph J.A., Simon J.A., Lin A., McKenna G.J., Baden H.P., Halperin A.J., Ponten J. A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc. Natl. Acad. Sci USA. 88:1991;10124-10128.
15. Brusick D. Mutagenicity and carcinogenicity correlations between bacteria and rodents. Ann. NY Acad. Sci. 407:1983;164-176.
16. Clive D., Flamm W.G., Machesko M.R., Gernheim N.J. A mutational assay system using the thymidine kinase locus in mouse lymphoma cells. Mutation Res. 16:1972;77-87.
17. +/- mouse lymphoma cells. Mutagenesis. 5:1990;191-197.
18. Cole, Arlett J.C., Green M.H.L., Lowe J., Muriel W. A comparison of the agar cloning and microtitration techniques for assaying cell survival and mutation frequency in L5178Y mouse lymphoma cells. Mutation Res. 111:1983;371-386.
19. Combes R.D., Stopper H., Caspary W.J. The use of L5178Y mouse lymphoma cells to assess the mutagenic, clastogenic and aneugenic properties of chemicals. Mutagenesis. 10:1995;403-408.
20. Cohen S.M., Ellwein L.B. Cell proliferation in carcinogenesis. Science. 249:1990;1007-1011.
21. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process - first American Cancer Society award lecture on cancer epidemiology and prevention. Cancer Res. 52:1992;6735-6740.
22. +/- human lymphoblasts, genetically engineered for expression of cytochromes P450. Toxicology. 82:1993;89-104.
23. Cunningham M.L. Role of increased DNA replication in the carcinogenic risk of nonmutagenic chemical carcinogens. Mutation Res. 1996;. this issue.
24. Dietrich D.R., Swenberg J.A. The presence of alpha-globulin is necessary for d-limonene promotion of male rat kidney tumors. Cancer Res. 51:1991;3512-3521.
25. Dipple A., Moschel R.C., Hudgins W.R. Selectivity of alkylation and aralkylation of nucleic acid components. Drug Metab. Rev. 13:1982;249-268.
26. Eastmond D.A., Pinkel D. Detection of aneuploidy and aneuploidy-inducing agents in human lymphocytes using fluorescence in situ hybridization with chromosome-specific DNA probes. Mutation Res. 234:1990;303-318.
27. Elespuru R.K., Yarmolinsky M.B. A colorimetric assay of lysogenic induction designed for screening potential carcinogenic and carcinostatic agents. Environ. Mutagen. 1:1979;65-78.
28. Elespuru R.K., Stupar L.L., Gordon J.A. Discrimination of mutagenic intermediates derived from alkylating agents by mutational patterns generated in Escherichia coli. Carcinogenesis. 12:1991;1161-1167.
29. Farber E. The multistep nature of cancer. Cancer Res. 44:1984;4217-4223.
30. Fearon E.R., Vogelstein B.A. A genetic model for colorectal tumorigenesis. Cell. 61:1990;759-767.
31. Fornace A.J. Jr., Jackman J., Hollander M.C., Hoffman-Liebermann B., Liebermann D.A. Genotoxic-stress-response genes and growth-arrest genes. Ann. NY Acad. Sci. 663:1992;139-153.
32. Foulds L. The experimental study of tumor progression; a review. Cancer Res. 14:1954;327-339.
33. Fuscoe J.C., Zimmerman L.J., Harrington-Brock K., Moore M. Large deletions are tolerated at the hprt locus of in vivo derived human T-lymphocytes. Mutation Res. 283:1992;255-262.
34. Gee P., Maron D., Ames B.N. Detection and classification of mutagens: a set of base-specific Salmonella tester strains. Proc. Nat. Acad. Sci USA. 91:1994;11606-11610.
35. Ghanayem B.I., Maronpot R.R., Matthews H.B. Role of chemically induced cell proliferation in ethyl acrylate-induced forestomach carcinogenesis. Chemically induced cell proliferation: implications for risk assessment. 1991;337-346 Wiley-Liss, New York.
36. Goldsworthy T.L., Conolly R.B., Fransson-Steen R. Apoptosis and cancer risk assessment. Mutation Res. 1996;. this issue.
37. Greenblatt M.S., Bennett W.P., Hollstein M., Harris C.C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 54:1994;4855-4878.
38. Hanawalt P.C. Heterogeneity of DNA repair at the gene level. Mutation Res. 247:1991;203-211.
39. Hansen M.F., Cavenee W.K. Genetics of cancer predisposition. Cancer Res. 47:1987;5518-5527.
40. Harris C.C., Weston A., Willey J.C., Trivers G.E., Mann D.L. Biochemical and molecular epidemiology of human cancer: indicators of carcinogen exposure, DNA damage, and genetic predisposition. Environ. Health Perspect. 75:1987;109-119.
41. Harris C.C. p53: at the crossroads of molecular carcinogenesis and risk assessment. Science. 262:1993;1980-1981.
42. Hartman P.E., Hartman Z., Stahl R.C., Ames B.N. Classification of spontaneous and induced mutations in the histidine operon of Salmonella. Adv. Genet. 16:1971a;1-34.
43. Hartwell L. Defects in cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell. 71:1992;543-546.
44. Hartwell L.H., Weinert T.A. Checkpoints: controls that assure the order of cell cycle events. Science. 246:1989;629-633.
45. Hass B.S., Littlefield N.A. Two in vitro transformation assays to predict, verify, and explore carcinogenesis. Lab. Animal. 1995;37-43.
46. Heddle J.A., Swiger R.R. Risk estimation from somatic mutation assays. Mutation Res. 1996;. this issue.
47. Heidelberger C., Freeman A.E., Pienta R.J., Sivak A., Bertram J.S., Casto B.C., Dunkel V.C., Francis M.W., Kakunaga T., Little J.B., Schechtman L.M. Cell transformation by chemical agents - a review and analysis of the literature. A report of the U.S. Environmental Protection Agency Gene-Tox Program. Mutation Res. 114:1990;283-385.
48. Herrlich P., Angel P., Rahmsdorf J.H. The mammalian genetic stress response. Adv. Enzyme Regul. 25:1986;485-504.
49. Hoffmann D., Hoffmann I., Wynder E.L. Lung cancer and the changing cigarette. O'Neill I.K., Chen J., Bartsch H. Relevance to human cancer of N-nitroso compounds, tobacco smoke and mycotoxins. IARC Scientific Publications No. 105. 1991;451. Lyon.
50. Holmquist G.P. Review article: Chromosome bands, their chromatin flavors, and their functional features. Am. J. Hum. Genet. 51:1992;17-37.
51. Hollstein M., Sidransky D., Vogelstein B., Harris C.C. p53 mutations in human cancers. Science. 253:1991;49-53.
52. Hsu I.C., Metcalf R.A., Sun T., Welsh J.A., Wang N.J., Harris C.C. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature. 350:1991;427-428.
53. IARC. Hepatitis viruses: Monograph No. 59. 1994a;255 IARC, Lyon. (summary).
54. IARC. Schistosomes, liver flukes and Helicobacter pylori: Monograph No. 61. 1994b;241 IARC, Lyon. (summary).
55. Isfort R.J., LeBoeuf R.A. Application of in vitro cell transformation assays to predict the carcinogenic potential of chemicals. Mutation Res. 1996;. this issue.
56. Knudsen A.G. Jr. Overview: genes that predispose to cancer. Mutation Res. 247:1991;190-815.
57. Kricker M.C., Drake J.W., Radman M. Duplication-targeted DNA methylation and mutagenesis in the evolution of eukaryotic chromosomes. Proc. Natl. Acad. Sci. USA. 89:1992;1075-1079.
58. La D.K., Swenberg J.A. DNA adducts: biological markers of exposure and potential applications to risk assessment. Mutation Res. 1996;. this issue.
59. Levine A.J. The tumor suppressor genes. Annu. Rev. Biochem. 62:1993;623-651.
60. Lijinsky W. Life-span and cancer: the induction time of tumors in diverse animal species treated with nitrosodieth-ylamine. Carcinogenesis. 14:1993;2373-2375.
61. Littlefield N.A., Farmer J.H., Gaylor D.W., Sheldon W.G. Effects of dose and time in a long-term, low-dose carcinogenic study. J. Environ. Pathol. Toxicol. 3:1980;17-34.
62. Livingstone L.R., White A., Sprouse J., Livanos E., Jacks T., Tlsty T.D. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell. 70:1992;923-935.
63. MacGregor J.T., Farr S., Tucker J.D., Heddle J.A., Tice R.R., Turtletaub K.W. New molecular endpoints and methods for routine toxicity testing, Fund. Appl. Toxicol. 26:1995a;156-173.
64. MacGregor J.T., Tucker J.D., Eastmond D.A., Wyrobek A.J. Integration of cytogenetic assays with toxicology studies. Environ. Mol. Mutagen. 25:1995b;328-337.
65. Matthews E.J., Spalding J.W., Tennant R.W. Transformation of BALB/c-3T3 cells: V. Transformation responses of 168 chemicals compared with mutagenicity in Salmonella and carcinogenicity in rodent bioassays. Environ. Health Perspect. Suppl. 101:(Suppl. 2):1993;347-482.
66. McCann J., Spingarn N.E., Kobori J., Ames B.N. Detection of carcinogens as mutagens: bacterial tester strains with R factor plasmids. Proc. Natl. Acad. Sci. USA. 72:1975a;979-983.
67. McCann J., Choi E., Yamasaki E., Ames B.N. Detection of carcinogens as mutagens in the Salmonella/microsome test: assay of 300 chemicals. Proc. Natl. Acad. Sci USA. 72:1975b;5135-5139.
68. Mirsalis J.C., Monforte J.A., Winegar R.A. Transgenic animal models for measuring mutations in vivo. Crit. Rev. Toxicol. 24:1994;255-280.
69. Morrison V., Ashby J. A preliminary evaluation of the performance of the Muta Mouse and Big Blue (lacI) transgenic mouse mutation assays. Mutagenesis. 9:1994;367-375.
70. Mullis K., Faloona F., et al. Specific enzyme amplification of DNA in vitro: the polymerase chain reaction, 1986 [classical article]. Biotechnology. 24:1992;17-27.
71. Nebert D.W. Role of genetics and drug metabolism in human cancer risk. Mutation Res. 247:1991;267-281.
72. Ozturk M., et al. p53 mutation in hepatocellular carcinoma after aflatoxin exposure. Lancet. 338:1991;1356-1359.
73. Papadopoulos N., Nicolaides N.C., Ying-Fei W., Ruben S.M., Carter K.C., Rosen C.A., Haseltine W.A., Fleischmann R.D., Fraser C.M., Adams M.D., Venter J.C., Hamilton S.R., Petersen G.M., Watson P., Lynch H.T., Peltomaki P., Mecklin J.P., de la Chapelle A., Kinzler K.W., Vogelstein B. Mutation of a mutL homolog in hereditary colon cancer. Science. 263:1994;1625.
74. Paules R.S., Levedakou E.N, Wilson S.J., Innes C.L., Rhodes N., Tlsty T.D., Galloway D.A., Donehower L.A., Tainsky M.A., Kaufmann W.K. Defective G2 checkpoint function in cells from individuals with familial cancer syndromes. Cancer Res. 55:1995;1763-1773.
75. Perera F.P. The significance of DNA and protein adducts in human biomonitoring studies. Mutation Res. 205:1988;255-269.
76. Perera F.P., Dickey C., Santella R., O'Neill J.P., Albertini R.J., Ottman R., Tsai W.Y., Mooney L.A., Savela K., Hemminki K. Carcinogen-DNA adducts and gene mutation in foundry workers with low-level exposure to polycyclic aromatic hydrocarbons. Carcinogenesis. 15:1994;2905-2910.
77. Phillips D.H., Schoket B., Hewer A., Bailey E., Kostic S., Vincze I. Influence of cigarette smoking on the levels of DNA adducts in human bronchial epithelium and white blood cells. Int. J. Cancer. 46:1990;569-575.
78. Poirier M.C., Beland F.A. DNA adduct measurements and tumor incidence during chronic carcinogen exposure in animal models: implications for DNA adduct-based human cancer risk assessment. Chem. Res. Toxicol. 5:1992;749-755.
79. Poirier M.C. Human exposure monitoring, dosimetry, and cancer risk assessment: the use of antisera specific for carcinogen-DNA adducts and carcinogen-modified DNA. Drug Metab. Rev. 26:1994;87-109.
80. Pool-Zobel B.L., Lotzmann N., Knoll M., Kuchenmeister F., Lambertz R., Leucht U., Schroeder H-G., Schmezer P. Detection of genotoxic effects in human gastric and nasal mucosa cells isolated from biopsy samples. Environ. Mol. Mutagen. 24:1994;23-45.
81. Quan TaiHao. Differential mutagenicity and cytotoxicity of (+ / -)-benzo[a]pyrene-trans-7,8-dihydrodiol and (+ / -)-anti-benzo[a]pyrene-trans-7,8-dihydrodiol-9,10-epoxide in genetically engineered human fibroblasts. Mol. Carcinogen. 12:1995;91-102.
82. 32P-Postlabeling methods for DNA adduct detection: overview and critical evaluation. Drug Metab. Rev. 26:1994;67-85.
83. Robbins W.A., Segraves R., Pinkel D., Wyrobek A.J. Detection of aneuploid human sperm by fluorescence in situ hybridization: Evidence for a donor difference in frequency of sperm disomic for chromosomes I and Y. Am. J. Hum. Genet. 52:1993;799-807.
84. Rosenkranz H.S., Klopman G. Structural relationships between mutagenicity, maximum tolerated dose, and carcinogenicity in rodents. Environ. Mol. Mutagen. 21:1993;193-206.
85. Schmid W. The micronucleus test for cytogenetic analysis. Hollaender A. Chemical Mutagens. Vol. 4:1976;31-53 Plenum Press, New York.
86. Shelby M.D., Zeiger E. Activity of human carcinogens in the Salmonella and rodent bone-marrow cytogenetics tests. Mutation Res. 234:1990;257-261.
87. Shepard S.E., Lutz W.K., Schlatter C. The lacI transgenic mouse mutagenicity assay: Quantitative evaluation in comparison to tests for carcinogenicity and cytogenetic damage in vivo. Mutation Res. 306:1994;119-128.
88. Singh N.P., McCoy M.T., Tice R.R., Schneider E.L. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp. Cell Res. 175:1988;184-191.
89. Sofuni T., et al. Validation study of the mouse lymphoma TK assay and mammalian cell chromosomal aberration asssay. Mutation Res. 1996;. in press.
90. Stankowski L.F., Tindall K.R. Characterization of the AS52 cell line for use in mammalian cell mutagenesis studies. Moore M.M., DeMarini D.M., de Serres F.J., Tindall K.R. Mammalian Cell Mutagenesis, Banbury Report No. 28. 1987;71-79 Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
91. Stone J.G., Jones N.J., McGregor A.D., Waters R. Development of a human biomonitoring assay using buccal mucosa: comparison of smoking-related DNA adducts in mucosa versus biopsies. Cancer Res. 55:1995;1267-1270.
92. Strauss B. The origin of point mutations in human tumor cells. Cancer Res. 52:1992;249-253.
93. Tennant R.W., Margolin B.H., Shelby M.D., Zeiger E., Haseman J.K., Spalding J., Caspary W., Resnick M., Stasiewicz S., Anderson B. Prediction of chemical carcinogenicity in rodents from in vitro genetic toxicity assays. Science. 236:1987;933-941.
94. Tennant R.W., French J.E., Spalding J.W. Identifying chemical carcinogens and assessing potential risk in short-term bioassays using transgenic mouse models. Environ. Health Perspect. 103:(10):1995;942-950.
95. Tice R.R., Andrews P.W., Hirai O., Singh N.P. The single cell gel (SCG) assay: An electrophoretic technique for the detection of DNA damage in individual cells. Witmer C.R., Snyder R.R., Jollow D.J., Kalf G.F., Kocsis J.J., Sipes I.G. Biological Reactive Intermediates IV, Molecular and Cellular Effects and Their Impact on Human Health. 1991;157-164 Plenum Press, New York.
96. Tlsty T.D., Briot A., Gualberto A., Hall I., Hess S., Hixon M., Kuppuswamy D., Romanov S., Sage M., White A. Genomic instability and cancer. Mutation Res. 337:1995;1-7.
97. Tucker J.D., Preston R.J. Chromosome aberrations, micronuclei, aneuploidy, sister chromatid exchanges, and cancer risk assessment. Mutation Res. 1996;. this issue.
98. White I.N.H., de Matteis F., Davies A., Smith L.L., Crofton-Sleigh C., Venitt S., Hewer A., Phillips D.H. Genotoxic potential of tamoxifen and analogues in female Fischer 344/n rats, DBA/2 and C57B1/6 mice and in human MCL-5 cells. Carcinogenesis. 13:1992;2197-2203.
99. Williams J.R., Russell J., Dicello J.F., Mabry M.H. The genotype of the human cancer cell: implications for risk analysis. Mutation Res. 1996;. this issue.
100. Witkin E. Ultraviolet mutagenesis and the SOS response in Escherichia coli: A personal perspective. Environ. Mol. Mutagen. 14:(Suppl. 16):1989;30-34.